GlassScriptPhysician profile
Jamie Jo Lee
NPI 1356973192
$6,270.63
in general payments reported to CMS, 2019-2025
37 companies · $975 in 2025
The $975 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,201 · 2022: $1,796 · 2023: $1,017 · 2024: $1,281 · 2025: $975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,273.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $900.33 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $520.65 | 2021-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $468.67 | 2022-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $379.87 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $358.11 | 2021-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $357.31 | 2021-2025 | Trelegy Ellipta |
| Lundbeck LLC | $357.06 | 2024-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $324.40 | 2021-2024 | Rexulti |
| Amgen INC. | $301.91 | 2021-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $284.99 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $232.48 | 2021-2023 | Ajovy |
| Pfizer INC. | $185.24 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $171.57 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $163.06 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Kowa Pharmaceuticals America, INC. | $158.16 | 2021-2023 | Livalo, Seglentis |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $108.91 | 2023 | Quviviq |
| Exact Sciences Corporation | $102.54 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $92.90 | 2021-2023 | |
| Dexcom, INC. | $88.19 | 2023-2024 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $81.26 | 2021-2023 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $80.73 | 2021-2023 | Trintellix |
| Astellas Pharma US INC | $78.67 | 2022-2025 | Veozah |
| Biogen, INC. | $67.63 | 2021-2025 | Zurzuvae |
| Corium, LLC | $51.55 | 2023-2024 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.55 | 2021-2024 | Jardiance |
| Amarin Pharma, INC. | $41.25 | 2021 | |
| Genzyme Corporation | $37.19 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $35.73 | 2022 | |
| Aimmune Therapeutics, INC. | $34.76 | 2024-2025 | Zenpep |
| Paratek Pharmaceuticals, INC. | $33.82 | 2024-2025 | Nuzyra |
| Phathom Pharmaceuticals, INC. | $20.49 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $20.30 | 2021 | |
| Axsome Therapeutics, INC. | $19.11 | 2025 | Auvelity |
| Halozyme INC | $18.94 | 2023 | |
| Nestle Healthcare Nutrition INC. | $17.33 | 2021 | |
| Supernus Pharmaceuticals, INC. | $15.60 | 2024 | Xyosted, Qelbree |
| Advanced Oxygen Therapy INC. | $13.37 | 2025 | Topical Oxygen Chamber For Extremities |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.